GAITHERSBURG, Md., Oct. 12 /PRNewswire-FirstCall/ -- MedImmune, Inc. has
been named to Deloitte's Maryland Technology Fast 50 program for the ninth
consecutive year. The Technology Fast 50 is a ranking of the fastest-growing
technology companies in the area by Deloitte & Touche LLP. Rankings are based
on the percentage growth over five years from 2000-2004.
"We are proud to again be named by Deloitte & Touche as one of the area's
fastest growing companies," said Lota S. Zoth, MedImmune's chief financial
officer. "In 2004, MedImmune's core business continued to achieve solid
growth, with product sales surpassing $1 billion for the first time in the
company's history. We also made significant advances in our clinical pipeline,
with three programs moving into Phase 3 development."
"Deloitte's Maryland Technology Fast 50 companies have shown the strength,
vision and temerity to succeed in today's very competitive technology
environment," said Andrew Harrs, principal, Deloitte & Touche LLP in McLean,
Virginia, and southeast region telecommunications, media and technology
practice leader. "We applaud the success of MedImmune and acknowledge it as
one of the very few to accomplish such a fast growth rate over the past five
Along with Deloitte & Touche LLP, the Maryland Technology Fast 50 program
is hosted by Wilmer Cutler Pickering Hale and Dorr. Media sponsors include PR
Newswire and WTOP Radio Network.
To qualify for the Technology Fast 50, companies must have had operating
revenues of at least $50,000 in 2000 and $1,000,000 in 2004, be headquartered
in North America, and be a "technology company," defined as a company that
owns proprietary technology that contributes to a significant portion of the
company's operating revenues; or devotes a significant proportion of revenues
to research and development of technology.
Winners of the 15 regional Technology Fast 50 programs in the United
States and Canada are automatically entered in the Deloitte Technology Fast
500 program, which ranks North America's top 500 fastest growing technology
companies. For more information on the Fast 50 or Fast 500 programs, visit
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With approximately 2,000 employees
worldwide, MedImmune is headquartered in Maryland. For more information, visit
the company's website at http://www.medimmune.com.
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss
Verein, its member firms, and their respective subsidiaries and affiliates.
Deloitte Touche Tohmatsu is an organization of member firms around the world
devoted to excellence in providing professional services and advice, focused
on client service through a global strategy executed locally in nearly 150
countries. With access to the deep intellectual capital of 120,000 people
worldwide, Deloitte delivers services in four professional areas - audit, tax,
consulting and financial advisory services - and serves more than one-half of
the world's largest companies, as well as large national enterprises, public
institutions, locally important clients and successful, fast-growing global
growth companies. Services are not provided by the Deloitte Touche Tohmatsu
Verein, and, for regulatory and other reasons, certain member firms do not
provide services in all four professional areas.
As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any
of its member firms has any liability for each other's acts or omissions. Each
of the member firms is a separate and independent legal entity operating under
the names "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu" or other
This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the company's filings with the U.S. Securities and
Exchange Commission. The company is developing several products for potential
future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or
that, even if such regulatory clearance were received, such products would
ultimately achieve commercial success.
SOURCE MedImmune, Inc.
Jamie Lacey, +1-301-398-4035
John Filler, +1-301-398-4086
all of MedImmune, Inc.